ABSTRACT ␤-Site amyloid precursor protein (APP)-cleaving enzyme (BACE) 1 cleavage of amyloid precursor protein is an essential step in the generation of the potentially neurotoxic and amyloidogenic A␤42 peptides in Alzheimer's disease. Although previous mouse studies have shown brain A␤ lowering after BACE1 inhibition, extension of such studies to nonhuman primates or man was precluded by poor potency, brain penetration, and pharmacokinetics of available inhibitors. In this study, a novel tertiary carbinamine BACE1 inhibitor, tertiary carbinamine (TC)-1, was assessed in a unique cisterna magna ported rhesus monkey model, where the temporal dynamics of A␤ in cerebrospinal fluid (CSF) and plasma could be evaluated. TC-1, a potent inhibitor (IC 50 ϳ 0.4 nM), has excellent passive membrane permeability, low susceptibility to P-glycoprotein transport, and lowered brain A␤ levels in a mouse model. Intravenous infusion of TC-1 led to a significant but transient lowering of CSF and plasma A␤ levels in conscious rhesus monkeys because it underwent CYP3A4-mediated metabolism. Oral codosing of TC-1 with ritonavir, a potent CYP3A4 inhibitor, twice daily over 3.5 days in rhesus monkeys led to sustained plasma TC-1 exposure and a significant and sustained reduction in CSF sAPP␤, A␤40, A␤42, and plasma A␤40 levels. CSF A␤42 lowering showed an EC 50 of ϳ20 nM with respect to the CSF [TC-1] levels, demonstrating excellent concordance with its potency in a cell-based assay. These results demonstrate the first in vivo proof of concept of CSF A␤ lowering after oral administration of a BACE1 inhibitor in a nonhuman primate.
integral membrane protein with a single transmembrane domain that undergoes initial cleavage by ␤-site APP-cleaving enzyme (BACE) 1 producing an N-terminal secreted fragment of APP (sAPP␤) and a membrane-anchored C-terminal fragment (CTF␤) (Vassar, 2005) . CTF␤ is further cleaved at a site within its transmembrane domain by the ␥-secretase enzyme complex leading to the production of various A␤ peptides, predominantly 40 and 42 residues in length (Hardy and Selkoe, 2002) . Mutations in APP that enhance ␤-site cleavage are linked to some familial variants of AD, whereas other mutations alter the specificity of the ␥-secretase cleavage, leading to production of the more aggregation-prone and neurotoxic A␤42 peptides (Steiner et al., 1999) . In contrast, alternative APP processing by ␣-secretase followed by ␥-secretase results in generation of a longer secreted fragment (sAPP␣) and a shorter peptide fragment (P3), neither of which are believed to be amyloidogenic (Kojro and Fahrenholz 2005) .
BACE1 is considered a promising target for brain A␤ lowering based partially on the fact that BACE1 knockout (KO) mice have extremely low brain A␤ levels, do not accumulate amyloid plaques, and show enhanced ␣-secretase processing of APP (Cai et al., 2001; Luo et al., 2001; Ohno et al., 2004) . BACE1 KO mice were originally reported to be viable with subtle phenotypic changes (Roberds et al., 2001; Harrison et al., 2003) . More recently, early lethality (Dominguez et al., 2005) , cognitive deficits in aged mice (Laird et al., 2005) , and alterations in brain neuregulin-1 processing in early development (Hu et al., 2006; Willem et al., 2006) have been noted in some variants of these animals. The origin of these phenotypic differences is unknown. With respect to neuregulin, direct pharmacological inhibition of BACE1 in adult mice showed no significant effect on its processing at doses where brain A␤ levels were significantly lowered (Sankaranarayanan et al., 2008) . Considering all published evidence, BACE1 appears to be a viable target to mediate brain A␤ lowering in Alzheimer's disease.
BACE1 is an aspartyl protease with a catalytic site similar to several pharmacologically important enzymes, such as HIV protease and renin. Similar to these targets, development of potent, brain-penetrant BACE1 inhibitors with acceptable pharmacokinetic properties has been extremely challenging (Ghosh et al., 2007) . Aspartyl protease inhibitors require multiple binding elements to achieve adequate affinity within their large and open catalytic site (Hong et al., 2000) and thus tend to be large in size. Inhibitors generally undergo rapid metabolism and provide poor systemic exposure. The structural requirements for binding also impart high susceptibility to P-glycoprotein (P-gp) transport, thus reducing brain concentrations of BACE-1 inhibitors (Mahar Doan et al., 2002) . A few BACE1 inhibitors have been shown to lower brain A␤ levels after direct intracranial administration (Asai et al., 2006; Nishitomi et al., 2006; Sankaranarayanan et al., 2008) or via peripheral administration at relatively high doses in murine models (Chang et al., 2004; Stachel et al., 2006; Hussain et al., 2007; Stanton et al., 2007) . However, the lack of potent inhibitors that also possess good pharmacokinetic and brain penetration properties have prevented evaluation of BACE1 inhibitors in larger animals, such as nonhuman primates.
In this study, we report on a novel potent tertiary carbinamine BACE1 inhibitor, TC-1 (inhibitory concentration IC 50 , ϳ0.4 nM) with excellent passive permeability and low P-gp susceptibility. Robust brain A␤ lowering was observed in mice after intraperitoneal administration and CSF A␤ lowering in rhesus monkeys after intravenous infusion with TC-1. However, the duration of action and oral bioavailability of TC-1 was severely limited by rapid CYP3A4-mediated metabolism. Based on the precedent established by the clinical use of HIV aspartyl protease inhibitors in combination with inhibitors of CYP3A4, codosing of TC-1 with ritonavir was investigated (Zeldin and Petruschke, 2004) . Dramatic improvements in the in vivo half-life and oral bioavailability of TC-1 were attained by this strategy. Twice daily oral administration of TC-1 with ritonavir led to sustained and significant reduction in CSF and plasma A␤ concentrations over 3.5 days in rhesus monkeys. These results demonstrate the first in vivo proof of concept that CNS A␤ lowering can be achieved after oral administration of a BACE1 inhibitor in nonhuman primates.
Materials and Methods
In Vitro Assays to Characterize the Properties of TC-1. TC-1 is a tertiary carbinamine
, with chemical makeup C 2 6H 35 ClN 6 O 4 S (mol. wt. 563.12). The in vitro BACE1, BACE2, and cathepsin D activity assays were performed exactly as described previously (Pietrak et al., 2005) . The cell-based assay to measure activity of TC-1 on sAPP␤ secretion from cells was performed as described previously (Pietrak et al., 2005; Shi et al., 2005 ). An in vitro Renin activity assay was performed similar to that described previously (Wang et al., 1993) . Human recombinant Renin (Proteos, Inc., Kalamazoo, MI) was preincubated with test compounds for 30 min. Renin substrate (Invitrogen, Carlsbad, CA) was then added to all wells and incubated for 90 min at 37°C while protected from light. The reaction was stopped and resulting fluorescence read on a SpectraMax plate reader (Molecular Devices, Sunnyvale, CA).
Human MDR1 transfectants, mouse mdr1a transfectants, and their parental cell line LLC-PK1 (porcine renal epithelial cells) were kindly provided by Dr. Alfred H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) and used under a license agreement. Cynomolgus MDR1-transfected LLC-PK1 cells were purchased and used under license agreement from BD Gentest (Woburn, MA). Directional transport studies to determine P-gp transport ratios were performed according to published methods (Yamazaki et. al, 2001; Booth-Genthe et al., 2006) using Multiscreen Caco-2 96-well filter plates (Millipore Corporation, Billerica, MA). Passive membrane permeability values were determined as the average of the permeability coefficients for apical to basolateral (A-B) and basolateral to apical (B-A) transport in the parental LLC-PK1 cells, whereas the P-glycoprotein ratio is measured as the ratio of B-A/A-B permeation.
BACE1 Inhibitor Studies in Mice. APP-YAC mice expressing the human WT-APP transgene under control of human APP promoter elements in a yeast artificial chromosome vector were used in these studies (Lamb et al., 1993) . All animal procedures were done in accordance with guidelines from the Institutional Animal Care and Use Committee at Merck. BACE1 inhibitor TC-1 was formulated in 25% dimethyl sulfoxide with 75% polyethylene glycol 300. Mice were dosed intraperitoneally at 5 ml/kg at a dose of 100 mg/kg. After the desired time of treatment, mice were euthanized in a CO 2 chamber, and plasma and brains were collected and stored frozen at Ϫ80°C until analysis.
Cisterna Magna Ported Rhesus Monkey Model. Rhesus monkeys chronically implanted with catheters in the cisterna magna allowed repeated sampling of CSF and plasma in conscious animals at ASPET Journals on September 22, 2017 jpet.aspetjournals.org (Gilberto et al., 2003) . All animal procedures were done in accordance with guidelines from the Institutional Animal Care and Use Committee at Merck.
The intravenous dosing study was a full crossover 3 period design, with 1-week washout between each period (n ϭ 6). The treatments were vehicle (5% dextrose) and BACE1 inhibitor TC-1 at low and high doses, administered via intravenous bolus followed by 4-h continuous infusion paradigm. In rhesus studies, the hydrochloride salt form of TC-1 was used, compared with the free base or trifluoroacetic acid salt of TC-1 in mice studies. The hydrochloride salt had improved solubility in aqueous vehicles. No differences were found between the free base of TC-1 and salt form of TC-1 in mice brain A␤ lowering (data not shown). The oral dosing study was a full crossover 2 period design with 1-week washout between the two periods (n ϭ 8). TC-1 was formulated in 20% polyethylene glycol 200 in 5% dextrose, whereas ritonavir was formulated in 20% ethanol along with 30% polyethylene glycol 200, 10% Cremophor, and 40% citric acid. Animals were dosed with ritonavir at 10 mg/kg p.o., 2 h before either: 1) TC-1 (15 mg/kg p.o.) or 2) vehicle twice daily for 3.5 consecutive days. In these studies, 1 ml of CSF and 2 ml of blood (in K 2 EDTA) were collected at each time point of sampling. CSF was stored frozen in 250-l aliquots, whereas plasma (ϳ800 l), prepared from lowspeed centrifugation, was stored in 200-l aliquots. Whole-blood samples were taken 20 h before the start and 96 h after the final dose for complete blood count and clinical chemistry. TC-1 and ritonavir levels in CSF and plasma from rhesus studies and TC-1 in brain and plasma samples from mice studies were measured using standard mass spectrometry methods (Xu et al., 2007) .
Antibodies. A␤ N-terminal antibody 6E10 (Covance Research Products, Princeton, NJ), which recognizes amino acids 3 to 8 of A␤ (Kim et al., 1988) , was used as a capture antibody for A␤ species in mouse brain homogenates and rhesus CSF and plasma samples. Neoepitope-specific antibodies were used to detect A␤40 and A␤42 peptides, similar to that described earlier (Ida et al., 1996) . sAPP␣ from rhesus CSF was captured using 6E10, whereas sAPP␤ was captured using an sAPP␤_KM-specific neoepitope polyclonal antibody, as described earlier (Sankaranarayanan et al., 2008) . The P2-1 antibody directed to the N terminus of APP (Invitrogen, Carlsbad, CA) was used as the detection antibody for both sAPP␣ and sAPP␤ in CSF samples (Van Nostrand et al., 1992) . Detection antibodies for all ELISA assays were conjugated with alkaline phosphatase using the EZ-link maleimide-activated alkaline phosphatase kit (Pierce Chemical, Rockford, IL) using standard protocols.
Measurement of A␤40, A␤42, sAPP␤, and sAPP␣ by Sandwich ELISA. Brain homogenates, CSF, and/or plasma samples were run in ELISA assays for various analytes as described below. A␤40, A␤42, and sAPP␣ were captured in ELISA plates coated with 6E10 antibody, whereas a KM-neoepitope antibody was used to capture sAPP␤. Black polystyrene plates (Corning Inc., Corning, NY) were coated overnight with the 5 g/ml capture antibody, washed, and then blocked with 3% bovine serum albumin in phosphate-buffered saline or Superblock in phosphate-buffered saline (Pierce Chemical). The plates were then stored at 4°C until use. Fifty to 100 l of brain homogenate, CSF, or plasma samples from individual animals was added per well in duplicate, followed by 50 l of detection antibody conjugated with alkaline phosphatase (final IgG concentration, ϳ0.1 g/ml). A␤40 and A␤42 were detected with C-terminal neoepitope antibodies, whereas the N-terminal P2-1 antibody was used to detect both sAPP␤ and sAPP␣.
Standard curves were prepared for mouse brain A␤ analysis, using APP-KO brain matrix prepared in an identical manner to the APP-YAC mice brain samples, to convert raw signal to concentration. For quantitation of the various CSF or plasma analytes, CSF and plasma were immunodepleted of A␤ or sAPP species and used to prepare standard curves with synthetic or cell culture-derived pure peptides. Standards for A␤40, A␤42 (American Peptide Co., Inc., Sunnyvale, CA), sAPP␤, and sAPP␣ peptides (S4316, S9564; Sigma-Aldrich, St. Louis, MO) were stored in frozen aliquots at Ϫ80°C and used to prepare standard curve dilutions. CSF samples were diluted 4-fold for A␤40 and A␤42 assays and 50-to 200-fold for CSF sAPP␣ and sAPP␤ assays, respectively. Plasma samples were diluted 3-fold for the plasma A␤40 assay. After overnight incubation at 4°C, plates were washed and developed using alkaline phosphatase substrate (Applied Biosystems, Foster City, CA). Luminescence counts were measured using an LJL Analyst (Molecular Devices).
Data Analysis. In all assays, standards run in duplicate were fit using a third order spline fit, coefficients were determined, and unknowns were converted to concentrations. All statistical analyses were done on log-transformed data, and results were reported after transforming back to the original scale. The lower limit of detection of brain A␤40 and A␤42 assays was 3.1 and 1.6 pM, respectively (ϳ33 and ϳ17 fmol/g after adjusting for brain weight). The lower limit of detection for CSF A␤40 and A␤42 was 6.3 and 1.6 pM, and 6.3 pM for plasma A␤40 assay, whereas it was 130 and 32 pM for CSF sAPP␤ and sAPP␣ assays, respectively. Spline fits to standard curves and statistical analysis were performed using JMP (SAS Institute, Cary, NC). Graphs and figures were prepared using JMP (SAS Institute) and Origin (OriginLab Corp., Northampton, MA) and collated with Adobe Illustrator (Adobe Systems, Mountain View, CA). Box and whisker plots were used to display data from mice studies as described previously (Sankaranarayanan et al., 2008) .
In rhesus monkey studies, summary time course plots are displayed as the geometric mean Ϯ S.E. A global mixed effects model was built for each individual analyte, including the treatment, time, sequence, period, treatment crossed with time as fixed effects, and baseline average analyte levels as a covariate, and subjects were nested within treatments as random effect before comparisons across groups were done. From this model, pairwise comparisons were performed between groups to determine statistically significant differences. Linear fits were performed to determine correlation coefficients between various analytes. Statistical significance is denoted conventionally by: ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; and ‫,ءءء‬ p Ͻ 0.001, using Tukey-Kramer honestly significant difference or Student's t test, as indicated.
Results

TC-1 Is a Potent and Selective BACE1 Inhibitor and Lowers Brain A␤ Levels in Mice.
Although some previously reported nonhydroxyethylamine and tertiary carbinamine BACE1 inhibitors have shown good passive membrane permeability and reduced P-gp susceptibility (Rajapakse et al., 2006; Lindsley et al., 2007; Stauffer et al., 2007) , leading to brain exposure in murine studies (Moore et al., 2007; Stanton et al., 2007) , most of these compounds were P-gp substrates or had poor potency against BACE1. In this study, we report on a novel tertiary carbinamine inhibitor (TC-1), which is highly potent against BACE1 (IC 50 ϳ 0.4 nM) and can inhibit sAPP␤ secretion from cells (IC 50 ϳ40 nM) (Fig. 1, A and B ) with selectivity against other aspartyl proteases (Fig. 1A) . TC-1 showed very good passive membrane permeability and low susceptibility to transport by mouse, monkey, or human P-gp (Fig. 1A) . Although high plasma protein binding (Fig.  1A ) was expected to limit brain exposure of TC-1, we hypothesized that the subnanomolar potency and improved transport properties would enable adequate brain exposures to elicit brain A␤ lowering after peripheral dosing.
Acute administration of TC-1 in APP-YAC mice at a dose of 100 mg/kg i.p. led to significant brain A␤40 lowering at both 2-h (26%) and 4-h (29%) time points (Fig. 1C) . The average total plasma [TC-1] was 25 and 13 M, whereas the average total brain [TC-1] was 1.6 and 1.8 M, respectively, at the 2-and 4-h time points. The brain/plasma ratio was 6 and 14%,
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respectively. In other independent experiments, similar results were observed. For example, administration of TC-1 at 100 mg/kg i.p. led to ϳ33% lowering of brain A␤40 and ϳ21% lowering of brain A␤42 after a 3-h treatment, with excellent correlation between brain A␤40 and A␤42 (Supplemental Fig. 1 ). Plasma and brain [TC-1] were 17 and 1.7 M, respectively, with brain/plasma ratio of 10%. Because the brains were not perfused before harvest in these studies, there is a potential confound because of the approximately 3 to 4% brain volume occupied by vasculature, thus altering the true brain compound levels (Hitchcock and Pennington, 2006) . Thus, TC-1 appears to show at best marginal brain penetration. Because the unbound fraction in the presence of mouse plasma proteins is Ͻ2% (Fig. 1A) , the free plasma concentration is calculated to be ϳ300 to 400 nM. Therefore, assuming equilibrium of the free fraction across compartments, free brain [TC-1] concentrations are not expected to exceed 400 nM. Despite these limitations, peripheral administration of TC-1 led to significant brain A␤ lowering.
Intravenous Infusion of TC-1 in Rhesus Monkeys Led to Robust Plasma and CSF A␤ Lowering. As a first step toward examining central BACE1 inhibition in rhesus monkeys, acute intravenous infusion of TC-1 was performed, and the effects on CSF and plasma A␤ analytes were evaluated. A three-way crossover study with vehicle (5% dextrose), low dose (1.2 mg/kg i.v. bolus followed by a 4-h infusion at 16 g/kg/min), and high dose (3.5 mg/kg i.v. bolus followed by 4 h infusion at 48 g/kg/min) of TC-1 was performed. CSF and plasma samples were collected at Ϫ22, Ϫ20, and Ϫ1 h before intravenous bolus and at 2, 4, 6, 8, and 24 h after onset of infusion ( Fig. 2A, top) . Plasma and CSF [TC-1] showed time-and dose-dependent changes over the course of the experiment ( Fig. 2A , middle and bottom). CSF and plasma [TC-1] levels were maintained during the 4-h infusion and then rapidly declined over the next few hours. The average plasma [TC-1] was 1.6 and 3.8 M during infusion, whereas the corresponding average CSF [TC-1] was 7 and 20 nM at the low and high doses of TC-1, respectively. Although plasma [TC-1] levels were measurable at the 24-h time point, CSF [TC-1] levels were below the limit of detection beyond 8 h in the low-dose group.
A time-dependent decline in plasma A␤40 levels was observed after treatment with TC-1 (Fig. 2B) . TC-1 led to baseline adjusted plasma A␤40 reduction of ϳ45 and ϳ65%, in the low-and high-dose groups, respectively, at the 4-h time point. Plasma A␤40 levels returned toward baseline as early as 8 h and recovered completely by 24 h. In the vehicle group, we observed an ϳ25% decline during the time period of infusion with TC-1, relative to baseline. Although we do not understand the nature of this decline in the vehicle group during infusion, it was not statistically different from baseline (p Ͼ 0.1).
A time-dependent decline in CSF A␤40 (Fig. 2C ) and A␤42 levels (Fig. 2D) were observed after treatment with TC-1. TC-1 led to a baseline adjusted CSF A␤40 reduction of ϳ21% in the low-dose group and ϳ42% in the high-dose group at the 4-h time point. TC-1 led to a baseline-adjusted reduction of CSF A␤42 of ϳ35% in the high-dose group at the 4-h time point but showed no significant change in the low-dose group. CSF A␤40 and A␤42 levels showed no significant changes after infusion of vehicle. Both CSF A␤40 and 42 levels showed recovery toward baseline as early as the 8-h time point and recovered completely by 24 h. There was a significant correlation between CSF A␤40 and A␤42 levels in this study (r ϭ 0.96, p Ͻ 0.001, n ϭ 144) (data not shown).
Plasma Exposure of TC-1 Is Enhanced after Codosing with Ritonavir. The intravenous infusion study indicated that sustained infusion was necessary to achieve sufficient CNS exposure of TC-1 to lower CSF A␤ analytes. It was hypothesized that if in vivo pharmacokinetic properties of TC-1 could be augmented, it would be possible to test oral dosing of TC-1 on CSF A␤ lowering in rhesus monkeys. In vitro metabolic stability studies using liver microsomes from multiple species showed that TC-1 was almost completely Fig. 1 . TC-1, a potent BACE1 inhibitor led to brain A␤ lowering in APP-YAC mice. A, structure of TC-1, a tertiary carbinamine BACE1 inhibitor. TC-1 is a potent and selective BACE1 inhibitor. The IC 50 values for BACE1, BACE2, renin, and cathepsin D were derived from in vitro enzymatic assays. Cellular potency was measured in a cell line expressing an APP substrate with an optimized artificial ␤-site mutation (KMDA 3 NFEV), which after ␤-site cleavage leads to the production of sAPP␤_NF, as published by Shi et al. (2005) . Passive membrane permeability (Papp) of TC-1 was good, and it was not a P-gp substrate because the B-A/A-B ratio was low but exhibits high protein binding. P-gp ratio and plasma protein binding were measured in three independent species. B, titration of TC-1 in in vitro BACE1 enzymatic assay (black squares) and cell-based sAPP␤ secretion assay (red circles), respectively, show IC 50 s of 0.4 and 40 nM, respectively (traces are logistic fits to the data). The data are plotted as the mean Ϯ range (n ϭ 2). C, TC-1 (100 mg/kg i.p.) led to significant brain A␤40 lowering in APP-YAC mice at 2 and 4 h after dosing (p Ͻ 0.001, Tukey-Kramer honestly significant difference, n ϭ 6 -8 animals). Similar results were obtained in n ϭ 5 independent experiments.
metabolized within 10 min (data not shown). Furthermore, clearance of TC-1 by liver microsomes was inhibited by treatment with ritonavir, a potent CYP3A4 inhibitor (data not shown). These in vitro studies suggest that TC-1 was predominantly cleared by the liver P450 microsomal enzyme, CYP3A4. To test this hypothesis in vivo, pharmacokinetic experiments were designed to examine the plasma exposure and clearance of TC-1 after intravenous or oral dosing of TC-1 with or without ritonavir. Ritonavir is an HIV protease inhibitor currently used in humans to enhance the pharmacokinetic properties of other HIV protease inhibitors in combination highly active antiretroviral therapies (Zeldin and Petruschke, 2004) .
TC-1 was rapidly cleared after a 1 mg/kg i.v. bolus in rhesus monkeys (plasma t 1/2 , ϳ1 h; CL p ϭ 24 ml/min/kg). Oral dosing of TC-1 at 10 mg/kg led to peak plasma levels of less than 30 nM (Fig. 3) , with extremely poor bioavailability (Ͻ1%). In contrast, when TC-1, either intravenously or orally, was codosed with ritonavir at 10 mg/kg p.o., plasma exposures were dramatically increased (Fig. 3) . Plasma clearance was reduced from 24 to 7 ml/min/kg, and t 1/2 increased from 1 to ϳ3 h. Oral bioavailability was increased from Ͻ1 to 2 . Acute intravenous infusion of TC-1 led to significant CSF and plasma A␤ lowering in rhesus monkeys. A three-way crossover study with vehicle, low dose of TC-1 (1.2 mg/kg i.v. bolus with 4 h infusion at 16 g/kg/min), and a high dose (TC-1 at 3.5 mg/kg i.v. bolus followed by 4 h infusion at 48 g/kg/min) was tested (n ϭ 6). A, plasma and CSF pharmacokinetics after intravenous infusion of TC-1. Top, dosing paradigm and sampling time points for CSF and plasma samples (downward arrows). TC-1 was administered as an acute intravenous bolus at time 0, followed by a 4-h intravenous infusion (black horizontal bar). Time course of plasma [TC-1] (middle) and CSF [TC-1] (bottom) levels. Horizontal dotted line, lower limit of detection for TC-1 in plasma and CSF, respectively. B, dose-and time-dependent reduction of plasma A␤40 was observed after intravenous infusion with TC-1. A significant lowering of plasma A␤40 was observed at 2 (p Ͻ 0.001), 4 (p Ͻ 0.001), 6 (p Ͻ 0.001), and 8 (p Ͻ 0.01) h after intravenous infusion of a high dose of TC-1, whereas a significant lowering was observed at 4 (p Ͻ 0.001) and 6 (p Ͻ 0.05) h at the low dose of TC-1, relative to vehicle. C, doseand time-dependent reduction of CSF A␤40 was observed after intravenous infusion with TC-1. A significant lowering of CSF A␤40 was observed at 2 (p Ͻ 0.01), 4 (p Ͻ 0.001), 6 (p Ͻ 0.001), and 8 (p Ͻ 0.05) h after intravenous infusion of a high dose of TC-1 relative to vehicle. The low dose of TC-1 showed no significant differences compared with vehicle. D, dose-and time-dependent reduction of CSF A␤42 was observed after intravenous infusion with TC-1. A significant lowering of CSF A␤42 was observed at 2 (p Ͻ 0.05), 4 (p Ͻ 0.001), 6 (p Ͻ 0.001), and 8 (p Ͻ 0.05) h after intravenous infusion of a high dose of TC-1 relative to vehicle. The low dose of TC-1 showed no significant differences compared with vehicle. Similar results were obtained in n ϭ 3 independent experiments with TC-1.
135
at ASPET Journals on September 22, 2017 jpet.aspetjournals.org ϳ83%, and plasma area under the curve exposure increased from less than 0.1 M/h in the absence of ritonavir to 39 M/h with ritonavir. Taken together, ritonavir enhanced oral bioavailability and enhanced plasma TC-1 exposure in rhesus monkeys and enabled testing the effect of longer term oral dosing with TC-1 in rhesus monkeys.
Oral Codosing of Ritonavir with TC-1 Led to Sustained CSF and Plasma A␤ Lowering in Rhesus Monkeys. Rhesus monkeys were codosed with ritonavir and BACE1 inhibitor TC-1 to determine whether sustained plasma exposure with TC-1 would lead to sustained CSF A␤ lowering. A two-way crossover study was performed in n ϭ 8 animals treated with: 1) ritonavir/vehicle and 2) ritonavir/ TC-1. Ritonavir (10 mg/kg p.o.) was dosed 2 h before BACE1 inhibitor TC-1 (15 mg/kg p.o.) or vehicle, twice daily. The dosing paradigm (Fig. 4A, top) led to seven dosing time points of TC-1 with ritonavir over 3.5 days, with one peak (P) and two trough (T) plasma and CSF samples being collected on each day for pharmacokinetic and pharmacodynamic analysis.
Plasma and CSF [TC-1] showed sustained compound exposure over 3.5 days after the ritonavir/TC-1 codosing paradigm (Fig. 4A, bottom) . The average plasma [TC-1] was 2.7 Ϯ 0.6 M and CSF [TC-1] was 25 Ϯ 4 nM over the entire time course of treatment. The calculated free plasma concentration of TC-1 (ϳ99% protein bound) was ϳ27 nM, suggesting that CSF levels were in equilibrium with free plasma . The average plasma ritonavir levels were comparable between the ritonavir/vehicle (650 Ϯ 125 nM) and ritonavir/ TC-1 (740 Ϯ 182 nM) groups over the time course of treatment.
A robust lowering of plasma A␤40 levels was observed in the ritonavir/TC-1 arm compared with the ritonavir/vehicle arm of the study (Fig. 4B) . The average plasma A␤40 levels, over the treatment period, showed 61% reduction (p Ͻ 0.001), relative to the ritonavir/vehicle arm of study. The average Fig. 4 . Oral codosing of ritonavir with TC-1 led to significant and sustained CSF A␤ lowering. Two-way crossover study with ritonavir/vehicle and ritonavir/TC-1 (n ϭ 8). A, top, TC-1 dosing paradigm (red arrows) and time points for harvesting CSF and plasma samples (black arrows). Ritonavir (10 mg/kg p.o.) was administered 2 h before TC-1 at 15 mg/kg p.o., twice daily over 3.5 days. CSF and plasma samples were collected at baseline (Ϫ20 and Ϫ3 h), P samples were collected 4 h after the morning dose of TC-1, whereas T samples were collected 3 h before the morning and evening dose of TC-1. Finally, a recovery sample was collected 96 h after the final dose of TC-1. Bottom, time course of plasma [TC-1] (filled red squares) and CSF levels (open red squares). Dotted line, lower limit of detection for TC-1 in this study. B, time course of plasma A␤40 levels over 3.5 days in animals codosed with ritonavir/vehicle (black filled squares) and ritonavir/TC-1 (red filled circles). Significant plasma A␤40 lowering, averaged over the entire 3.5 days of dosing, was observed with ritonavir/TC-1 compared with ritonavir/vehicle (p Ͻ 0.001, pair-wise Student's t test). Time course of CSF A␤40 (C), CSF A␤42 (D), CSF sAPP␤ (E), and CSF sAPP␣ levels (F), respectively, over 3.5 days in animals codosed with ritonavir/vehicle and ritonavir/TC-1. Significant CSF A␤40 lowering of 42% (p Ͻ 0.001,), CSF A␤42 lowering of 43% (p Ͻ 0.001), and CSF sAPP␤ lowering of 41% (p Ͻ 0.001), respectively, were observed relative to ritonavir/vehicle group averaged over the entire 3.5 days of dosing (pair-wise Student's t test). No significant differences were observed between the treatment groups in CSF sAPP␣. CSF A␤40, CSF A␤42, and CSF sAPP␤ levels, during treatment, showed 42% (p Ͻ 0.001), 43% (p Ͻ 0.002), and 41% (p Ͻ 0.001) reduction, respectively, relative to the ritonavir/vehicle arm (Fig. 4, C-E) . The demonstration of CSF sAPP␤ lowering provides evidence of inhibition of ␤-site cleavage of APP by TC-1. A trend toward elevation in CSF sAPP␣ levels was observed after treatment with ritonavir/TC-1, whereas in mice, a robust elevation was observed previously in brains after inhibition of BACE1 (Hussain et al., 2007; Sankaranarayanan et al., 2008) . CSF sAPP␤ and A␤ analytes showed slightly greater lowering at the peak (P) or ϩ4-h time point after dosing compared with the T time points, indicating that maximal lowering was associated with peak plasma or CSF [TC-1] levels. Plasma A␤40, CSF A␤40, and CSF A␤42 analytes were fairly stable across all time points in the ritonavir/ vehicle group and similar to that in the vehicle/vehicle group, analyzed independently in a third arm of this study (data not shown). Taken together, these results provide the first demonstration of significant and sustained CSF sAPP␤ and A␤ lowering and plasma A␤ lowering after oral administration of a BACE1 inhibitor in a nonhuman primate.
Multiparameter Correlations of CSF sAPP␤, A␤, and Plasma A␤ Analytes. BACE1 cleaves APP to produce the secreted N-terminal fragment of APP: sAPP␤ and a membrane-anchored CTF␤ (Vassar, 2005) . CTF␤ is further processed by the ␥-secretase enzyme complex, leading to the production of A␤ peptides. Because ␤-site cleavage of APP is the first step in the catabolic process that subsequently leads to the production of A␤ peptides, we examined the relationship between CSF sAPP␤ levels (direct readout of BACE1 inhibition) and CSF A␤42 levels (indirect readout of BACE1 inhibition) in samples from the above study. We further chose to correlate CSF sAPP␤ to CSF A␤42 because A␤42 is considered the amyloidogenic and toxic species in Alzheimer's disease. A significant correlation was observed between CSF sAPP␤ and CSF A␤42 levels (r ϭ 0.76, n ϭ 208, p Ͻ 0.001, ANOVA) (Fig. 5A) , illustrative of the key role that BACE1 plays in determining A␤ production. CSF sAPP␤ also showed significant correlation with CSF A␤40 levels (r ϭ 0.74, n ϭ 208, p Ͻ 0.0001, ANOVA) (data not shown). CSF A␤42 levels were tightly correlated with CSF A␤40 levels (r ϭ 0.90, n ϭ 208, p Ͻ 0.001, ANOVA) (Fig. 5B) , further strengthening our conclusion that TC-1 is a specific BACE1 inhibitor and thereby leads to a correlated reduction of sAPP␤, A␤40, and A␤42 levels. Finally, a significant but weaker correlation was observed between plasma A␤40 and CSF A␤40 (r ϭ 0.52, n ϭ 208, p Ͻ 0.001, ANOVA) (Fig. 5C ). These results suggest that CSF A␤40 lowering may be reflected in changes in plasma A␤40 levels. However, the weaker correlation suggests that other factors could contribute to the A␤40 signal in the plasma compartment. Taken together, the multiparameter correlations of APP processing Multiparameter correlations were performed using baseline normalized CSF and plasma APP processing analytes from the ritonavir/TC-1 codosing study in Fig. 4 . A, significant correlation between CSF A␤42 and CSF sAPP␤ levels (r ϭ 0.76, n ϭ 208, p Ͻ 0.001, ANOVA). B, significant correlation was observed between CSF A␤40 and CSF A␤42 levels (r ϭ 0.90, n ϭ 208 p Ͻ 0.001, ANOVA). C, significant correlation was observed between plasma A␤40 and CSF A␤40 levels (r ϭ 0.52, n ϭ 208 p Ͻ 0.001, ANOVA). The red lines in A to C are linear fits to the data. D, PK/PD relationship between baseline-normalized CSF A␤42 levels and CSF [TC-1] levels from individual samples from study presented in Fig. 4 . A logistic fit to data yielded a CSF [TC-1] EC 50 of ϳ20 nM for CSF A␤42 reduction.
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Relationship between CSF A␤42 Lowering and CSF [TC-1] Levels. CSF A␤42 levels showed a dose-dependent decline with respect to CSF [TC-1] levels (Fig. 5D ). Fits to the data revealed an EC 50 for CSF A␤42 lowering of ϳ20 nM CSF . These in vivo EC 50 values are in good agreement with the in vitro IC 50 of ϳ40 nM for sAPP␤ lowering in cell culture (Fig. 1A) . These results also provide excellent in vivo estimates for plasma and CSF exposure of TC-1 required for sustained CSF A␤ lowering. Taken together, these results suggest that if a potent BACE1 inhibitor with optimal passive permeability and P-gp liabilities can be made metabolically stable, a sustained and robust inhibition of CSF A␤ production can be achieved in primates.
Discussion
In this study, we demonstrate that TC-1, a potent and highly selective BACE1 inhibitor, led to significant lowering of brain A␤ levels in APP-YAC mice. Acute intravenous infusion of TC-1 in a cisterna magna ported rhesus monkey model showed significant but transient lowering of CSF A␤40 and 42 levels because TC-1 was predominantly metabolized by CYP3A4 in vivo. Thus, coadministration of TC-1 with ritonavir, a CYP3A4 inhibitor, led to dramatic improvement in bioavailability and plasma clearance in rhesus monkeys, improving brain exposure. Oral codosing of ritonavir with TC-1 led to significant CSF A␤ lowering for several days in rhesus monkeys. Thus, a potent and selective BACE1 inhibitor that has good membrane permeability, low P-gp susceptibility, and is orally bioavailable, can effectively lower CNS A␤ levels in a nonhuman primate model.
Development of potent and brain penetrant BACE1 inhibitors has been extremely challenging because of the presence of numerous charged residues in the unusually large active site of the enzyme (Hong et al., 2000) . Most of the published BACE1 inhibitors have been peptidic transition state isosteres and its derivatives. Although these inhibitors are very active on the enzyme, their in vivo utility has been limited by poor membrane permeability and susceptibility to P-gp transport and thus poor brain penetration. Brain A␤ lowering has been demonstrated previously in mice models with transition state isosteres via direct intracranial administration (Asai et al., 2006; Nishitomi et al., 2006; Sankaranarayanan et al., 2008) , parenteral administration (Chang et al., 2004; Stachel et al., 2006) , or via oral codosing with P-gp inhibitors (Hussain et al., 2007) , but none of these compounds were optimal in pharmacokinetic or brain exposure properties for testing in higher animals. TC-1 is a novel BACE1 inhibitor in which the previously reported isonicotinamide Stauffer et al., 2007) and isophthalate oxadiazole (Rajapakse et al., 2006) BACE1 inhibitors were merged to create a new structural class of inhibitors (Lindsley et al., 2007; Moore et al., 2007) . One such tertiary carbinamine (TC-1) is a potent BACE1 inhibitor (IC 50 , ϳ0.4 nM) that shows selectivity over BACE2 with no measurable activity against either renin or cathepsin D. In addition, TC-1 had good apparent membrane permeability (22 ϫ 10 Ϫ6 cm/s) and was not a P-gp substrate (B-A/A-B ratio of ϳ2.0 in mouse, human, and monkey), both properties being favorable for good brain penetration.
In the APP-YAC mouse model, 100 mg/kg TC-1 via intraperitoneal administration led to a significant lowering of brain A␤40 and A␤42 levels, with excellent correlation between the two analytes (Supplemental Fig. 1) . Thus, TC-1 is a novel BACE1 inhibitor that can lower brain A␤ levels in mice with a time course consistent with previously reported BACE1 inhibitors and the known in vivo half-life of A␤ in mice (Cirrito et al., 2003) .
An initial study in cisterna magna ported rhesus monkeys explored the effects of BACE inhibition with TC-1 using an intravenous bolus with 4-h infusion paradigm. A robust doseand time-dependent lowering of CSF and plasma A␤ analytes was observed. Although steady-state exposure was ϳ2 to 4 M in plasma during infusion, CSF exposures were only ϳ10 to 30 nM. It is likely that the CSF concentration is limited by high plasma protein binding (ϳ99% bound in rhesus monkey plasma). In fact, CSF levels are very similar to the plasma free [TC-1] during the infusion (ϳ20 -40 nM). CSF and plasma A␤ were lowered by ϳ20 to 40% compared with vehicle, with maximal lowering at the 4-h time point. A rapid recovery of both plasma and CSF A␤ levels was observed by 8 h, with complete recovery by 24 h. These rapid rates of recovery are consistent with the rapid decline of CSF and plasma [TC-1] levels and the short in vivo half-life of A␤ in these compartments (Bateman et al., 2006) . Intravenous infusion studies showed good correlation between CSF and plasma A␤ levels and [TC-1] level in these compartments and demonstrated the first evidence of in vivo A␤ lowering in a nonhuman primate model.
The short half-life of TC-1 of ϳ1 to 2 h and the technical challenges with longer duration intravenous infusions prevented longer duration infusion studies with TC-1. In vitro studies suggested that TC-1 was predominantly metabolized by CYP3A4 and could account for its rapid metabolic clearance in vivo. Ritonavir, an HIV protease inhibitor and a potent CYP3A4 inhibitor, reduced in vitro metabolism of TC-1 (ϳ10-fold). Pharmacokinetic studies also showed that codosing of TC-1 with ritonavir, increased the oral bioavailability of TC-1 (1-83%), dramatically improved its plasma half-life, reduced clearance, and thereby improved by severalfold the in vivo exposure of TC-1. The improvements in bioavailability and clearance of TC-1 when codosed with ritonavir are similar to that reported for HIV protease inhibitors in human clinical studies (Zeldin and Petruschke, 2004) and enabled multiday dosing of TC-1 in rhesus monkeys.
Codosing of ritonavir with TC-1 orally in rhesus monkeys led to a sustained lowering of plasma A␤40, CSF A␤40, A␤42, and sAPP␤ over 3.5 days. CSF A␤40 and A␤42 showed slightly greater lowering at the peak time point (4 h after AM dose) and declined modestly at the trough time points and was correlated with the plasma and CSF [TC-1] exposures, respectively. Taken together, these results demonstrate that sustained plasma and CSF exposure with TC-1 lead to sustained BACE1 inhibition in vivo. This conclusion is further corroborated by the significant correlation among CSF sAPP␤, A␤42, and A␤40 levels. Thus, a direct demonstration of CSF sAPP␤ lowering along with CSF A␤40 and A␤42 lowering with TC-1 suggests that in vivo BACE1 inhibition can significantly lower amyloidogenic peptides over a sustained period in a nonhuman primate.
Previous studies in mouse models have shown that BACE1 inhibition leads to a robust elevation of brain sAPP␣ levels at ASPET Journals on September 22, 2017 jpet.aspetjournals.org (Hussain et al., 2007; Sankaranarayanan et al., 2008) . Although CSF sAPP␣ trended upward with TC-1 compared with vehicle (10 -30%) and relative to baseline levels (15-40%), the elevations do not seem to be correlated in time with CSF sAPP␤ or A␤ lowering. The high degree of specificity of the CSF sAPP␣ ELISA over sAPP␤ and good dynamic range over a range of sAPP␣ concentrations above and below the endogenous levels lead us to conclude that the lack of CSF sAPP␣ elevation with TC-1 treatment is not because of assay-dependent issues (Supplemental Fig. 2) . These results suggest that CSF sAPP␣ concentrations in rhesus monkeys may be regulated differently than in mouse models that express mutant or wild-type human APP transgenes or could reflect the differential kinetics of equilibration of the analytes between the CSF and brain. Although plasma A␤40 was significantly correlated with CSF A␤40 levels, it appears that A␤40 is lowered to a greater extent in plasma than in the CSF (Fig. 4, B and C) . A possible reason could be that the effective brain concentration is lower than the CSF [TC-1] concentration (Hitchcock and Pennington, 2006 ).
An EC 50 of ϳ20 nM CSF [TC-1] levels was determined for CSF A␤42 lowering in the ritonavir/TC-1 codosing paradigm. Although the average total plasma [TC-1] levels ranged from 1 to 7 M, CSF [TC-1] levels were similar to the plasma free [TC-1] of ϳ10 to 70 nM, consistent with the good membrane permeability and lack of inherent susceptibility to P-gp (Lin, 2008) . The EC 50 for CSF A␤42 lowering is also in excellent agreement with in vitro IC 50 values for sAPP␤ lowering in cell culture. These results suggest that in vivo efficacy for a BACE1 inhibitor can be effectively predicted when in vitro properties and pharmacokinetic exposures in the CSF compartment are known.
Studies with ␥-secretase inhibitors have shown robust CNS A␤ lowering in numerous in vivo models (Barten et al., 2005; Best et al., 2005; Lanz et al., 2006) and, more recently, in humans (Siemers et al., 2007) . CSF A␤ lowering in mouse models and higher species occurred as predicted by in vitro potency of ␥-secretase inhibitors. In contrast to what is observed in the CNS, an elevation of plasma A␤ levels has been observed at lower levels of plasma exposure with gamma secretase inhibitors in many species (Lanz et al., 2006; Siemers et al., 2007) , the exact mechanism of which is unknown. Although this is the first study showing pharmacological inhibition of BACE1 in higher animal species, the current studies show no evidence for plasma A␤ elevations after treatment with BACE1 inhibitor TC-1 in rhesus monkeys.
In conclusion, we have shown that a potent and selective BACE1 inhibitor lacking P-gp substrate activity can effectively lower CSF A␤ levels in nonhuman primates. Future BACE1 inhibitor development will focus on maintaining potency while improving metabolic stability and retaining favorable brain penetration properties. Although numerous strategies are moving forward for antiamyloid therapies in human subjects, there is continued hope for development of a small molecule BACE1 inhibitor for human Alzheimer's disease. The increase in signal in neat CSF was parallel to that observed in immunodepleted CSF. These results suggest that the rhesus CSF sAPPα assay shows both selectivity and specificity over sAPPβ and can reliably detect both decreases and increases in sAPPα signal above endogenous levels.
